U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549984) titled 'A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis' on April 19.
Brief Summary: This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3033 in subjects with moderate-to-severe atopic dermatitis (AD). Approximately 16 eligible adult participants will be enrolled and sequentially assigned to one of two dose cohorts. Within each cohort, participants will be randomized in a 3:1 ratio to receive IBI3033 or matching placebo. The study consists of a screening period (up to 4 weeks), a 12-week treatment period, and a 4-...